Alexion Pharmaceuticals Inc. has won priority review from the U.S. Food and Drug Administration for its supplemental Biologics License Application for the company’s drug candidate Soliris to treat atypical Hemolytic Uremic Syndrome (aHUS).

Soliris is already FDA approved as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

SOURCE